Abstract
Inhibition of the blood fibrinolytic system (plasminogen/plasmin) occurs either at the level of plasminogen activators, regulated by specific plasminogen activator inhibitors (PAIs) or at the level of plasmin, mainly regulated by α2-antiplasmin (α2-AP). In this contribution, we focused on the roles of α2-AP in acute myocardial infarction and vascular remodeling associated with cardiovascular diseases. Our findings have identified a new target for the development of new therapeutics for the clinical therapy of cardiovascular diseases.
Keywords: antiplasmin, myocardial infarction, re-endothelialization, vegf, vegfr-1
Letters in Drug Design & Discovery
Title: Role of 2-Antiplasmin in Cardiovascular System
Volume: 2 Issue: 3
Author(s): En Shu, Hiroyuki Matsuno, Yasuo Kitajima and Osamu Kozawa
Affiliation:
Keywords: antiplasmin, myocardial infarction, re-endothelialization, vegf, vegfr-1
Abstract: Inhibition of the blood fibrinolytic system (plasminogen/plasmin) occurs either at the level of plasminogen activators, regulated by specific plasminogen activator inhibitors (PAIs) or at the level of plasmin, mainly regulated by α2-antiplasmin (α2-AP). In this contribution, we focused on the roles of α2-AP in acute myocardial infarction and vascular remodeling associated with cardiovascular diseases. Our findings have identified a new target for the development of new therapeutics for the clinical therapy of cardiovascular diseases.
Export Options
About this article
Cite this article as:
Shu En, Matsuno Hiroyuki, Kitajima Yasuo and Kozawa Osamu, Role of 2-Antiplasmin in Cardiovascular System, Letters in Drug Design & Discovery 2005; 2 (3) . https://dx.doi.org/10.2174/1570180053765129
DOI https://dx.doi.org/10.2174/1570180053765129 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adult Neurogenic and Antidepressant Effects of Adiponectin: A Potential Replacement for Exercise
CNS & Neurological Disorders - Drug Targets Metabolic Syndrome X is a Low-Grade Systemic Inflammatory Condition with its Origins in the Perinatal Period
Current Nutrition & Food Science Cell Therapy for Myocardial Regeneration
Current Molecular Medicine Pentraxins: CRP and PTX3 and Cardiovascular Disease
Inflammation & Allergy - Drug Targets (Discontinued) The Role of COX-2 in Heart Pathology
Cardiovascular & Hematological Agents in Medicinal Chemistry Evaluation and Management of Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Tissue Protective and Anti-Fibrotic Actions of Suramin: New Uses of an Old Drug
Current Clinical Pharmacology Substance P and its Inhibition in Ocular Inflammation
Current Drug Targets Calpains: Attractive Targets for the Development of Synthetic Inhibitors
Current Topics in Medicinal Chemistry Update in the Management of Diastolic Heart Failure
Current Vascular Pharmacology Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Cardiovascular Disease Burden and Risk Factors Before and After Kidney Transplant
Cardiovascular & Hematological Disorders-Drug Targets From Erythropoietin to Its Peptide Derivatives: Smaller but Stronger
Current Protein & Peptide Science Levosimendan: From Basic Science to Clinical Trials
Recent Patents on Cardiovascular Drug Discovery Efficacy and Cardiovascular Safety of Sulfonylureas
Current Drug Safety Di'ao Xinxuekang: Therapeutic Potential in Cardiovascular Diseases
Current Molecular Pharmacology The Potential Role of Erythropoietin as a Pleiotropic Agent in Post-cardiac Arrest Syndrome
Current Pharmaceutical Design The Use of Genomics and Proteomics for the Recognition of Transplantation Rejection of Solid Organs
Recent Patents on DNA & Gene Sequences Hydrogen Sulfide: A New Tool to Design and Develop Drugs
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) COX-2 Inhibitors and Cardiovascular Events: Deja Vu Du Jour
Vascular Disease Prevention (Discontinued)